Guardant Health, Inc.GH
Market cap
$12.7B
P/E ratio
| Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Precision oncology testing | - | - | - | 304 | 392 | 514 | 688 |
| Development services and other | - | - | - | 69 | 57 | 50 | 51 |
| Total revenue | 91 | 214 | 287 | 374 | 450 | 564 | 739 |
| Cost of precision oncology testing | - | - | - | 110 | 148 | 206 | 261 |
| Cost Of Development Services | - | - | - | 13 | 8 | 22 | 29 |
| Research and development expense | 51 | 86 | 150 | 263 | 374 | 367 | 348 |
| Sales and marketing expense | 53 | 78 | 107 | 192 | 300 | 295 | 365 |
| General and administrative expense | 36 | 61 | 193 | 207 | 164 | 156 | 180 |
| Other operating expense | - | - | - | - | - | 83 | - |
| Total costs and operating expenses | 184 | 297 | 542 | 785 | 994 | 1,129 | 1,183 |
| Loss from operations | -93 | -82 | -255 | -411 | -544 | -565 | -444 |
| Interest income | 5 | 14 | 10 | 4 | 6 | 35 | 54 |
| Interest expense | - | - | - | - | - | - | 3 |
| Other income (expense), net | 5 | 0 | 4 | 25 | -13 | 53 | -43 |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | - | - | - | - | -100 | - | - |
| Loss before provision for income taxes | - | - | - | -384 | -653 | -479 | -435 |
| Provision for income taxes | 0 | -2 | 0 | 0 | 1 | 1 | 1 |
| Net loss | -84 | -68 | -246 | -385 | -655 | -479 | -436 |
| Earnings Per Share, Basic | - | - | - | -4 | -6.41 | -4.28 | -3.56 |
| Earnings Per Share, Diluted | - | - | - | -4 | -6.41 | -4.28 | -3.56 |